Avantax Advisory Services, Inc. Contrafect Corp Transaction History

Avantax Advisory Services, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.09 - $0.19 $27,440 - $57,930	-304,899 Reduced 93.55%	21,009 $2,000
Q3 2022 Nov 01, 2022	BUY	$0.18 - $3.51 $11,853 - $231,147	65,854 Added 25.32%	325,908 $55,000
Q2 2022 Aug 02, 2022	BUY	$2.79 - $4.45 $17,222 - $27,469	6,173 Added 2.43%	260,054 $798,000
Q1 2022 Apr 27, 2022	BUY	$2.26 - $3.84 $12,041 - $20,459	5,328 Added 2.14%	253,881 $924,000
Q4 2021 Jan 24, 2022	BUY	$2.47 - $4.14 $2,161 - $3,622	875 Added 0.35%	248,553 $654,000
Q3 2021 Oct 21, 2021	SELL	$3.19 - $4.43 $3,049 - $4,235	-956 Reduced 0.38%	247,678 $1.01 Million
Q2 2021 Jul 29, 2021	BUY	$3.58 - $4.9 $82,014 - $112,254	22,909 Added 10.15%	248,634 $1.09 Million
Q1 2021 May 13, 2021	BUY	$4.46 - $6.68 $1.01 Million - $1.51 Million	225,725 New	225,725 $1.08 Million

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Avantax Advisory Services, Inc., based on Form 13F filings with the SEC.

Stay updated on Avantax Advisory Services, Inc. with notifications on news.